InflaRx(IFRX) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target
BenzingaMar 21 07:28 ET
Promising Prospects for InflaRx's Gohibic: Buy Rating Supported by Positive Phase 3 Developments and Market Potential
TipRanksMar 21 06:36 ET · Ratings
InflaRx Reports 2024 Results and Outlines 2025 Milestones
TipRanksMar 20 08:04 ET
INFLARX Earnings Results: $IFRX Reports Quarterly Earnings
Quiver QuantitativeMar 20 07:55 ET
InflaRx | 20-F: FY2024 Annual Report
SECMar 20 07:51 ET · Announcements
Express News | InflaRx's Cash, Cash Equivalents, And Marketable Securities Were €55.2M As Of December 31, 2024, Additional €28.7 Million (~$30M) In Gross Proceeds Subsequently Raised By An Underwritten Public Offering Extending Cash Runway Into 2027
BenzingaMar 20 07:35 ET

Comments

Teddy123

Mar 20 19:45

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

$InflaRx (IFRX.US)$
InflaRx 2024 Earnings Reveal Strong Cash Position and Major EU Drug Win

Trytosaveabit

Mar 20 19:41

YOY sales massive increase!

$InflaRx (IFRX.US)$ InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.95) by 17.89 percent. This is unchanged from the same period last year. The company reported quarterly sales of $165.79 thousand which missed the analyst consensus estimate of $306.80 thousand by 45.96 percent. This is a 162.79 percent increase over sales of $63.09 thousand the same period last year

Trytosaveabit

Mar 7 21:25

Reminder to keep eyes on for next few days! Data coming!

$InflaRx (IFRX.US)$ They have submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), to be presented during the 2025 American Academy of Dermatology (AAD) Annual Meeting, March 7 - 11, in Orlando, FL.

2

Jaguar8

Jan 16 12:21

🟤 Watchlist JANUARY 16,2025, Thursday. NFA.

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t appreciate my watchlist, STAY ...

126

9

Jaguar8

Jan 16 02:49

NEWS

$InflaRx (IFRX.US)$
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
Wednesday, 15th January at 12:30 pm
JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European Commission (EC) has granted marketing authorization under exceptional...

IFRX InflaRx

Trade Overview

Capital Trend

News

Comments

Market Insights